The Alexandria Real Estate Equities-backed oncology therapy developer is floating in the middle of its range to raise $82.5m in its initial public offering.

US-based exosome therapeutics developer Codiak BioSciences will go public today in an $82.5m initial public offering representing an exit for life science real estate investment trust Alexandria Real Estate Equities. The company is issuing 5.5 million shares on the Nasdaq Global Market priced at $15.00 each, in the middle of the offering’s $14 to $16…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.